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In a recent editorial, Dr Van Poznak addresses the important issue of managing bone health in breast cancer patients receiving adjuvant treatment with an aromatase inhibitor [1] . Based on the published results of three clinical trials using risedronate [2, 3] or ibandronate [4] , it is concluded that oral bisphosphonates may be considered a supportive therapy to treat or prevent osteoporosis in breast cancer patients receiving aromatase inhibitor adjuvant treatment.
We would like to comment on the results of those trials summarised in Table 1 of the editorial [1], focusing on patients with normal bone mineral density (BMD) or mild osteopaenia before starting treatment.
All three trials have shown that patients with normal BMD before starting treatment with anastrozole are at very low risk to develop osteoporosis, having a change in BMD less than -6% measured at 2 years in both the lumbar spine and hip, without any pharmacologic interven tion apart from receiving vitamin D and calcium supple ments [2] [3] [4] . Th e risk of osteoporosis is minimal and only a few patients might move to the osteopaenic region.
Considering the grey zone of treatment decisions in the management of patients with osteopaenia, we agree those trials provide very useful clinical data on the need for pharmacologic intervention and the eff ectiveness of oral bisphosphonates. Even though the BMD loss is less than -4% in both the lumbar spine and hip at 2 years under anastrozole treatment, the addition of oral bisphosphonates results in a change of up to +5.7% in BMD that is statistically signifi cant in all three trials -preventing eff ectively the development of osteoporosis. Furthermore, the mixed models analysis of the randomised arms in the ARBI trial [3] examining the percentage change from baseline in hip and lumbar spine BMD values suggests that higher baseline BMD values correspond to smaller changes at both 12 and 24 months, whereas patients' smaller BMD values at baseline exhibited a higher trend of BMD increase. In other words, patients starting treatment with anastrozole are not all at the same risk for bone loss, and also they respond to a diff erent extent to pharmacologic interventionspretreatment BMD estimation is an important factor in management decisions.
In conclusion, we estimate that all trials provide evidence supporting the use and eff ectiveness of oral bisphosphonates in patients already having BMD in the region of severe osteopaenia/osteoporosis when starting treatment with an aromatase inhibitor. On the contrary, for patients with normal BMD or mild osteopaenia at baseline, general preventive measures and BMD evaluation during follow-up visits seem to be adequate management since these patients are at low risk of developing severe osteopaenia or osteoporosis.
